Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides
- Nat Chem Biol. 2022 Oct;18(10):1076-1086. doi: 10.1038/s41589-022-01061-z.
- 1. Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
- 2. Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
- 3. Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, CA, USA.
- 4. Vivace Therapeutics, Inc., San Mateo, CA, USA.
- 5. Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.
- 6. Genus IntelliGen, Windsor, WI, USA.
- 7. Department of Pharmacology, University of California San Diego, La Jolla, CA, USA. [email protected].
- 8. Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. [email protected].
- # Contributed equally.
The Hippo pathway plays a key role in development, organ size control and tissue homeostasis, and its dysregulation contributes to Cancer. The LATS tumor suppressor kinases phosphorylate and inhibit the YAP/TAZ transcriptional co-activators to suppress gene expression and cell growth. Through a screen of Marine natural products, we identified microcolin B (MCB) as a Hippo activator that preferentially kills YAP-dependent Cancer cells. Structure-activity optimization yielded more potent MCB analogs, which led to the identification of phosphatidylinositol transfer proteins α and β (PITPα/β) as the direct molecular targets. We established a critical role of PITPα/β in regulating LATS and YAP. Moreover, we showed that PITPα/β influence the Hippo pathway via plasma membrane phosphatidylinositol-4-phosphate. This study uncovers a previously unrecognized role of PITPα/β in Hippo pathway regulation and as potential Cancer therapeutic targets.